Skip to main content
Erschienen in: Clinical Research in Cardiology 12/2014

01.12.2014 | Original Paper

Risk prediction with triglycerides in patients with stable coronary disease on statin treatment

verfasst von: Christian Werner, Anja Filmer, Marco Fritsch, Stephanie Groenewold, Stefan Gräber, Michael Böhm, Ulrich Laufs

Erschienen in: Clinical Research in Cardiology | Ausgabe 12/2014

Einloggen, um Zugang zu erhalten

Abstract

Background

The aim of the prospective Homburg Cream and Sugar study was to analyze the role of fasting and postprandial serum triglycerides (TG) as risk modifiers in patients with coronary artery disease (CAD).

Methods and results

A sequential oral triglyceride and glucose tolerance test was developed to obtain standardized measurements of postprandial TG kinetics and glucose in 514 consecutive patients with stable CAD confirmed by angiography (95% were treated with a statin). Fasting and postprandial TG predicted the primary outcome measure of cardiovascular death and hospitalizations after 48 months follow-up (fasting TG >150 vs. <106 mg/dl: Hazard ratio (HR) 1.79, 95% confidence interval (CI) 1.31–2.45, p = 0.0001; area under the curve >1120 vs. <750 mg/dl/5hr: HR 1.78, 95% CI 1.29–2.45, p = 0.0003). Parameters of the postprandial TG increase did not improve risk prediction compared to fasting TG. The number of cardiovascular deaths and myocardial infarctions was higher in the upper tertile of fasting TG (HR 1.79, 95%–CI 1.04–3.09, p = 0.03). Risk prediction by TG was independent of traditional risk factors, medication, glucose metabolism, LDL- and HDL-cholesterol. Total cholesterol, LDL- and HDL-cholesterol concentrations were not associated with the primary outcome.

Conclusions

Fasting serum triglycerides >150 mg/dl independently predict cardiovascular events in patients with coronary artery disease on guideline-recommended medication. Assessment of postprandial TG does not improve risk prediction compared to fasting TG in these patients.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Hulley SB, Rosenman RH, Bawol RD, Brand RJ (1980) Epidemiology as a guide to clinical decisions. The association between triglyceride and coronary heart disease. N Engl J Med 302:1383–1389PubMedCrossRef Hulley SB, Rosenman RH, Bawol RD, Brand RJ (1980) Epidemiology as a guide to clinical decisions. The association between triglyceride and coronary heart disease. N Engl J Med 302:1383–1389PubMedCrossRef
2.
Zurück zum Zitat Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, Thompson A et al (2009) Major lipids, apolipoproteins, and risk of vascular disease. JAMA 302:1993–2000PubMedCrossRef Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, Thompson A et al (2009) Major lipids, apolipoproteins, and risk of vascular disease. JAMA 302:1993–2000PubMedCrossRef
3.
Zurück zum Zitat Freiberg JJ, Tybjaerg-Hansen A, Jensen JS, Nordestgaard BG (2008) Nonfasting triglycerides and risk of ischemic stroke in the general population. JAMA, J Am Med Assoc 300:2142–2152CrossRef Freiberg JJ, Tybjaerg-Hansen A, Jensen JS, Nordestgaard BG (2008) Nonfasting triglycerides and risk of ischemic stroke in the general population. JAMA, J Am Med Assoc 300:2142–2152CrossRef
4.
Zurück zum Zitat Langsted A, Freiberg JJ, Nordestgaard BG (2008) Fasting and nonfasting lipid levels: influence of normal food intake on lipids, lipoproteins, apolipoproteins, and cardiovascular risk prediction. Circulation 118:2047–2056PubMedCrossRef Langsted A, Freiberg JJ, Nordestgaard BG (2008) Fasting and nonfasting lipid levels: influence of normal food intake on lipids, lipoproteins, apolipoproteins, and cardiovascular risk prediction. Circulation 118:2047–2056PubMedCrossRef
5.
Zurück zum Zitat Langsted A, Freiberg JJ, Tybjaerg-Hansen A, Schnohr P, Jensen GB, Nordestgaard BG (2011) Nonfasting cholesterol and triglycerides and association with risk of myocardial infarction and total mortality: the Copenhagen City Heart Study with 31 years of follow-up. J Intern Med 270:65–75PubMedCrossRef Langsted A, Freiberg JJ, Tybjaerg-Hansen A, Schnohr P, Jensen GB, Nordestgaard BG (2011) Nonfasting cholesterol and triglycerides and association with risk of myocardial infarction and total mortality: the Copenhagen City Heart Study with 31 years of follow-up. J Intern Med 270:65–75PubMedCrossRef
6.
Zurück zum Zitat Mora S, Rifai N, Buring JE, Ridker PM (2008) Fasting compared with nonfasting lipids and apolipoproteins for predicting incident cardiovascular events. Circulation 118:993–1001PubMedCentralPubMedCrossRef Mora S, Rifai N, Buring JE, Ridker PM (2008) Fasting compared with nonfasting lipids and apolipoproteins for predicting incident cardiovascular events. Circulation 118:993–1001PubMedCentralPubMedCrossRef
7.
Zurück zum Zitat Sarwar N, Danesh J, Eiriksdottir G, Sigurdsson G, Wareham N, Bingham S et al (2007) Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation 115:450–458PubMedCrossRef Sarwar N, Danesh J, Eiriksdottir G, Sigurdsson G, Wareham N, Bingham S et al (2007) Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation 115:450–458PubMedCrossRef
8.
Zurück zum Zitat Jackson KG, Poppitt SD, Minihane AM (2011) Postprandial lipemia and cardiovascular disease risk: Interrelationships between dietary, physiological and genetic determinants. Atherosclerosis Jackson KG, Poppitt SD, Minihane AM (2011) Postprandial lipemia and cardiovascular disease risk: Interrelationships between dietary, physiological and genetic determinants. Atherosclerosis
9.
Zurück zum Zitat Lopez-Miranda J, Williams C, Lairon D (2007) Dietary, physiological, genetic and pathological influences on postprandial lipid metabolism. Br J Nutr 98:458–473PubMedCrossRef Lopez-Miranda J, Williams C, Lairon D (2007) Dietary, physiological, genetic and pathological influences on postprandial lipid metabolism. Br J Nutr 98:458–473PubMedCrossRef
10.
Zurück zum Zitat Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18:499–502PubMed Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18:499–502PubMed
11.
Zurück zum Zitat Chapman MJ, Ginsberg HN, Amarenco P, Andreotti F, Boren J, Catapano AL et al (2011) Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J 32:1345–1361PubMedCentralPubMedCrossRef Chapman MJ, Ginsberg HN, Amarenco P, Andreotti F, Boren J, Catapano AL et al (2011) Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J 32:1345–1361PubMedCentralPubMedCrossRef
12.
Zurück zum Zitat Miller M, Stone NJ, Ballantyne C, Bittner V, Criqui MH, Ginsberg HN et al (2011) Triglycerides and cardiovascular disease: a scientific statement from the american heart association. Circulation 123:2292–2333PubMedCrossRef Miller M, Stone NJ, Ballantyne C, Bittner V, Criqui MH, Ginsberg HN et al (2011) Triglycerides and cardiovascular disease: a scientific statement from the american heart association. Circulation 123:2292–2333PubMedCrossRef
13.
14.
Zurück zum Zitat Moreton JR (1950) Chylomicronemia, Fat Tolerance, and Atherosclerosis. J Lab Clin Med 35:373–384 Moreton JR (1950) Chylomicronemia, Fat Tolerance, and Atherosclerosis. J Lab Clin Med 35:373–384
15.
16.
Zurück zum Zitat Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A (2007) Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 298:299–308PubMedCrossRef Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A (2007) Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 298:299–308PubMedCrossRef
17.
Zurück zum Zitat Lindman AS, Veierod MB, Tverdal A, Pedersen JI, Selmer R (2010) Nonfasting triglycerides and risk of cardiovascular death in men and women from the Norwegian Counties Study. Eur J Epidemiol 25:789–798PubMedCentralPubMedCrossRef Lindman AS, Veierod MB, Tverdal A, Pedersen JI, Selmer R (2010) Nonfasting triglycerides and risk of cardiovascular death in men and women from the Norwegian Counties Study. Eur J Epidemiol 25:789–798PubMedCentralPubMedCrossRef
18.
Zurück zum Zitat Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM (2007) Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA 298:309–316PubMedCrossRef Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM (2007) Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA 298:309–316PubMedCrossRef
19.
Zurück zum Zitat Boren J, Matikainen N, Adiels M, Taskinen MR (2014) Postprandial hypertriglyceridemia as a coronary risk factor. Clinica Chimica Acta, Intern J Clin Chem 431C:131–142CrossRef Boren J, Matikainen N, Adiels M, Taskinen MR (2014) Postprandial hypertriglyceridemia as a coronary risk factor. Clinica Chimica Acta, Intern J Clin Chem 431C:131–142CrossRef
20.
Zurück zum Zitat Brunzell JD (2007) Clinical practice. Hypertriglyceridemia. The New England J Medicine. 357:1009–1017CrossRef Brunzell JD (2007) Clinical practice. Hypertriglyceridemia. The New England J Medicine. 357:1009–1017CrossRef
21.
22.
Zurück zum Zitat Fontbonne A, Eschwege E, Cambien F, Richard JL, Ducimetiere P, Thibult N et al (1989) Hypertriglyceridaemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes. Results from the 11-year follow-up of the Paris Prospective Study. Diabetologia 32:300–304PubMedCrossRef Fontbonne A, Eschwege E, Cambien F, Richard JL, Ducimetiere P, Thibult N et al (1989) Hypertriglyceridaemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes. Results from the 11-year follow-up of the Paris Prospective Study. Diabetologia 32:300–304PubMedCrossRef
24.
Zurück zum Zitat Ridker PM (2008) Fasting versus nonfasting triglycerides and the prediction of cardiovascular risk: do we need to revisit the oral triglyceride tolerance test? Clin Chem 54:11–13PubMedCrossRef Ridker PM (2008) Fasting versus nonfasting triglycerides and the prediction of cardiovascular risk: do we need to revisit the oral triglyceride tolerance test? Clin Chem 54:11–13PubMedCrossRef
25.
Zurück zum Zitat Lahiri K, Rettig-Ewen V, Böhm M, Laufs U (2007) Perceived psychosocial stress and cardiovascular risk factors in obese and non-obese patients. Clin Res Cardiol: off J Ger Card Soc 96:365–374CrossRef Lahiri K, Rettig-Ewen V, Böhm M, Laufs U (2007) Perceived psychosocial stress and cardiovascular risk factors in obese and non-obese patients. Clin Res Cardiol: off J Ger Card Soc 96:365–374CrossRef
26.
Zurück zum Zitat Farhan S, Jarai R, Tentzeris I, Kautzky-Willer A, Samaha E, Smetana P et al (2012) Comparison of HbA1c and oral glucose tolerance test for diagnosis of diabetes in patients with coronary artery disease. Clin Res Cardiol: off J Ger Card Soc 101:625–630CrossRef Farhan S, Jarai R, Tentzeris I, Kautzky-Willer A, Samaha E, Smetana P et al (2012) Comparison of HbA1c and oral glucose tolerance test for diagnosis of diabetes in patients with coronary artery disease. Clin Res Cardiol: off J Ger Card Soc 101:625–630CrossRef
27.
Zurück zum Zitat Stone NJ, Robinson J, Lichtenstein AH, Merz CN, Blum CB, Eckel RH, et al. (2013) ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American college of cardiology/American heart association task force on practice guidelines. Circulation Stone NJ, Robinson J, Lichtenstein AH, Merz CN, Blum CB, Eckel RH, et al. (2013) ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American college of cardiology/American heart association task force on practice guidelines. Circulation
28.
Zurück zum Zitat Mora S, Wenger NK, Demicco DA, Breazna A, Boekholdt SM, Arsenault BJ et al (2012) Determinants of residual risk in secondary prevention patients treated with high- versus low-dose statin therapy: the Treating to New Targets (TNT) study. Circulation 125:1979–1987PubMedCentralPubMedCrossRef Mora S, Wenger NK, Demicco DA, Breazna A, Boekholdt SM, Arsenault BJ et al (2012) Determinants of residual risk in secondary prevention patients treated with high- versus low-dose statin therapy: the Treating to New Targets (TNT) study. Circulation 125:1979–1987PubMedCentralPubMedCrossRef
29.
Zurück zum Zitat Boekholdt SM, Arsenault BJ, Mora S, Pedersen TR, LaRosa JC, Nestel PJ et al (2012) Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. JAMA 307:1302–1309PubMedCrossRef Boekholdt SM, Arsenault BJ, Mora S, Pedersen TR, LaRosa JC, Nestel PJ et al (2012) Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. JAMA 307:1302–1309PubMedCrossRef
30.
Zurück zum Zitat Mora S, Glynn RJ, Boekholdt SM, Nordestgaard BG, Kastelein JJ, Ridker PM (2012) On-treatment non-high-density lipoprotein cholesterol, apolipoprotein B, triglycerides, and lipid ratios in relation to residual vascular risk after treatment with potent statin therapy: JUPITER (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin). J Am Coll Cardiol 59:1521–1528PubMedCentralPubMedCrossRef Mora S, Glynn RJ, Boekholdt SM, Nordestgaard BG, Kastelein JJ, Ridker PM (2012) On-treatment non-high-density lipoprotein cholesterol, apolipoprotein B, triglycerides, and lipid ratios in relation to residual vascular risk after treatment with potent statin therapy: JUPITER (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin). J Am Coll Cardiol 59:1521–1528PubMedCentralPubMedCrossRef
31.
Zurück zum Zitat Gitt AK, Junger C, Smolka W, Bestehorn K (2010) Prevalence and overlap of different lipid abnormalities in statin-treated patients at high cardiovascular risk in clinical practice in Germany. Clin Res Cardiol: off J Ger Card Soc 99:723–733CrossRef Gitt AK, Junger C, Smolka W, Bestehorn K (2010) Prevalence and overlap of different lipid abnormalities in statin-treated patients at high cardiovascular risk in clinical practice in Germany. Clin Res Cardiol: off J Ger Card Soc 99:723–733CrossRef
32.
Zurück zum Zitat Fihn SD, Gardin JM, Abrams J, Berra K, Blankenship JC, Dallas AP et al (2012) 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 60:e44–e164PubMedCrossRef Fihn SD, Gardin JM, Abrams J, Berra K, Blankenship JC, Dallas AP et al (2012) 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 60:e44–e164PubMedCrossRef
33.
Zurück zum Zitat Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C et al (2013) 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 34:2949–3003PubMedCrossRef Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C et al (2013) 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 34:2949–3003PubMedCrossRef
34.
Zurück zum Zitat National Cholesterol Education Program Expert Panel on Detection (2002) E, Treatment of High Blood Cholesterol in A. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106:3143–3421 National Cholesterol Education Program Expert Panel on Detection (2002) E, Treatment of High Blood Cholesterol in A. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106:3143–3421
35.
Zurück zum Zitat Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA et al (2009) Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120:1640–1645PubMedCrossRef Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA et al (2009) Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120:1640–1645PubMedCrossRef
36.
Zurück zum Zitat World Health Organization (2000) Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Orga Tech Rep ser 894:1–253 I-xii World Health Organization (2000) Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Orga Tech Rep ser 894:1–253 I-xii
37.
Zurück zum Zitat American Diabetes Association (2011) Executive summary: standards of medical care in diabetes–2011. Diabetes Care 34(Suppl 1):S4–S10 American Diabetes Association (2011) Executive summary: standards of medical care in diabetes–2011. Diabetes Care 34(Suppl 1):S4–S10
38.
Zurück zum Zitat Ewen S, Rettig-Ewen V, Mahfoud F, Böhm M, Laufs U (2014) Drug adherence in patients taking oral anticoagulation therapy. Clin Res Cardiol: off J Ger Card Soc 103:173–182CrossRef Ewen S, Rettig-Ewen V, Mahfoud F, Böhm M, Laufs U (2014) Drug adherence in patients taking oral anticoagulation therapy. Clin Res Cardiol: off J Ger Card Soc 103:173–182CrossRef
39.
Zurück zum Zitat Thygesen K, Alpert JS, White HD, Joint ESCAAHAWHFTFftRoMI, Jaffe AS, Apple FS et al (2007) Universal definition of myocardial infarction. Circulation 116:2634–2653PubMedCrossRef Thygesen K, Alpert JS, White HD, Joint ESCAAHAWHFTFftRoMI, Jaffe AS, Apple FS et al (2007) Universal definition of myocardial infarction. Circulation 116:2634–2653PubMedCrossRef
40.
Zurück zum Zitat Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE Jr et al (2013) 2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 61:e179–e347PubMedCrossRef Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE Jr et al (2013) 2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 61:e179–e347PubMedCrossRef
41.
Zurück zum Zitat Wang H, Eckel RH (2009) Lipoprotein lipase: from gene to obesity. Am J Physiol Endocrinol Metab. 297:E271–E288PubMedCrossRef Wang H, Eckel RH (2009) Lipoprotein lipase: from gene to obesity. Am J Physiol Endocrinol Metab. 297:E271–E288PubMedCrossRef
42.
Zurück zum Zitat Pavlic M, Xiao C, Szeto L, Patterson BW, Lewis GF (2010) Insulin acutely inhibits intestinal lipoprotein secretion in humans in part by suppressing plasma free fatty acids. Diabetes 59:580–587PubMedCentralPubMedCrossRef Pavlic M, Xiao C, Szeto L, Patterson BW, Lewis GF (2010) Insulin acutely inhibits intestinal lipoprotein secretion in humans in part by suppressing plasma free fatty acids. Diabetes 59:580–587PubMedCentralPubMedCrossRef
43.
Zurück zum Zitat Mihas C, Kolovou GD, Mikhailidis DP, Kovar J, Lairon D, Nordestgaard BG et al (2011) Diagnostic value of postprandial triglyceride testing in healthy subjects: a meta-analysis. Curr Vasc Pharmacol 9:271–280PubMedCrossRef Mihas C, Kolovou GD, Mikhailidis DP, Kovar J, Lairon D, Nordestgaard BG et al (2011) Diagnostic value of postprandial triglyceride testing in healthy subjects: a meta-analysis. Curr Vasc Pharmacol 9:271–280PubMedCrossRef
44.
Zurück zum Zitat Kolovou GD, Mikhailidis DP, Kovar J, Lairon D, Nordestgaard BG, Ooi TC et al (2011) Assessment and clinical relevance of non-fasting and postprandial triglycerides: an expert panel statement. Curr Vasc Pharmacol 9:258–270PubMedCrossRef Kolovou GD, Mikhailidis DP, Kovar J, Lairon D, Nordestgaard BG, Ooi TC et al (2011) Assessment and clinical relevance of non-fasting and postprandial triglycerides: an expert panel statement. Curr Vasc Pharmacol 9:258–270PubMedCrossRef
45.
Zurück zum Zitat Werner N, Kosiol S, Schiegl T, Ahlers P, Walenta K, Link A et al (2005) Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med 353:999–1007PubMedCrossRef Werner N, Kosiol S, Schiegl T, Ahlers P, Walenta K, Link A et al (2005) Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med 353:999–1007PubMedCrossRef
46.
Zurück zum Zitat Miller M, Cannon CP, Murphy SA, Qin J, Ray KK, Braunwald E (2008) Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 51:724–730PubMedCrossRef Miller M, Cannon CP, Murphy SA, Qin J, Ray KK, Braunwald E (2008) Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 51:724–730PubMedCrossRef
47.
Zurück zum Zitat Tentolouris N, Eleftheriadou I, Katsilambros N (2009) The effects of medications used for the management of dyslipidemia on postprandial lipemia. Curr Med Chem 16:203–217PubMedCrossRef Tentolouris N, Eleftheriadou I, Katsilambros N (2009) The effects of medications used for the management of dyslipidemia on postprandial lipemia. Curr Med Chem 16:203–217PubMedCrossRef
48.
Zurück zum Zitat Laufs U, Weintraub WS, Packard CJ (2013) Beyond statins: what to expect from add-on lipid regulating therapy? Eur Heart J 34:2660–2665PubMedCrossRef Laufs U, Weintraub WS, Packard CJ (2013) Beyond statins: what to expect from add-on lipid regulating therapy? Eur Heart J 34:2660–2665PubMedCrossRef
49.
Zurück zum Zitat Sacks FM, Carey VJ, Fruchart JC (2010) Combination lipid therapy in type 2 diabetes. N Engl J Med 363:692–694 author reply 4–5PubMedCrossRef Sacks FM, Carey VJ, Fruchart JC (2010) Combination lipid therapy in type 2 diabetes. N Engl J Med 363:692–694 author reply 4–5PubMedCrossRef
50.
Zurück zum Zitat Werner C, Hoffmann MM, Winkler K, Böhm M, Laufs U (2014) Risk prediction with proprotein convertase subtilisin/kexin type 9 (PCSK9) in patients with stable coronary disease on statin treatment. Vasc Pharm pii:S1537–1891(14)00057–3 Werner C, Hoffmann MM, Winkler K, Böhm M, Laufs U (2014) Risk prediction with proprotein convertase subtilisin/kexin type 9 (PCSK9) in patients with stable coronary disease on statin treatment. Vasc Pharm pii:S1537–1891(14)00057–3
51.
Zurück zum Zitat Ceriello A, Taboga C, Tonutti L, Quagliaro L, Piconi L, Bais B et al (2002) Evidence for an independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stress generation: effects of short- and long-term simvastatin treatment. Circulation 106:1211–1218PubMedCrossRef Ceriello A, Taboga C, Tonutti L, Quagliaro L, Piconi L, Bais B et al (2002) Evidence for an independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stress generation: effects of short- and long-term simvastatin treatment. Circulation 106:1211–1218PubMedCrossRef
52.
Zurück zum Zitat Gibson T, Fuller JH, Grainger SL, Jarrett RJ, Keen H (1974) Intralipid triglyceride and oral glucose tolerance. Diabetologia 10:97–100PubMedCrossRef Gibson T, Fuller JH, Grainger SL, Jarrett RJ, Keen H (1974) Intralipid triglyceride and oral glucose tolerance. Diabetologia 10:97–100PubMedCrossRef
53.
Zurück zum Zitat Wuesten O, Balz CH, Bretzel RG, Kloer HU, Hardt PD (2005) Effects of oral fat load on insulin output and glucose tolerance in healthy control subjects and obese patients without diabetes. Diabetes Care 28:360–365PubMedCrossRef Wuesten O, Balz CH, Bretzel RG, Kloer HU, Hardt PD (2005) Effects of oral fat load on insulin output and glucose tolerance in healthy control subjects and obese patients without diabetes. Diabetes Care 28:360–365PubMedCrossRef
54.
Zurück zum Zitat Lewis GF, O’Meara NM, Soltys PA, Blackman JD, Iverius PH, Pugh WL et al (1991) Fasting hypertriglyceridemia in noninsulin-dependent diabetes mellitus is an important predictor of postprandial lipid and lipoprotein abnormalities. J Clin Endocrinol Metab 72:934–944PubMedCrossRef Lewis GF, O’Meara NM, Soltys PA, Blackman JD, Iverius PH, Pugh WL et al (1991) Fasting hypertriglyceridemia in noninsulin-dependent diabetes mellitus is an important predictor of postprandial lipid and lipoprotein abnormalities. J Clin Endocrinol Metab 72:934–944PubMedCrossRef
55.
Zurück zum Zitat Sarwar N, Sandhu MS, Ricketts SL, Butterworth AS, Di Angelantonio E, Boekholdt SM et al (2010) Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet 375:1634–1639PubMedCrossRef Sarwar N, Sandhu MS, Ricketts SL, Butterworth AS, Di Angelantonio E, Boekholdt SM et al (2010) Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet 375:1634–1639PubMedCrossRef
Metadaten
Titel
Risk prediction with triglycerides in patients with stable coronary disease on statin treatment
verfasst von
Christian Werner
Anja Filmer
Marco Fritsch
Stephanie Groenewold
Stefan Gräber
Michael Böhm
Ulrich Laufs
Publikationsdatum
01.12.2014
Verlag
Springer Berlin Heidelberg
Erschienen in
Clinical Research in Cardiology / Ausgabe 12/2014
Print ISSN: 1861-0684
Elektronische ISSN: 1861-0692
DOI
https://doi.org/10.1007/s00392-014-0740-0

Weitere Artikel der Ausgabe 12/2014

Clinical Research in Cardiology 12/2014 Zur Ausgabe

Vorhofflimmern: Adipöse Patienten profitieren von dualer Kardioversion

11.06.2024 Vorhofflimmern Nachrichten

Bei stark übergewichtigen Personen lässt sich Vorhofflimmern mit zwei gleichzeitigen Schocks und einer insgesamt höheren Schockenergie effektiver stoppen als mit der herkömmlichen Single-Kardioversion, und das ohne höheres Komplikationsrisiko.

Auch ohne Blutung: Hämoglobinabfall nach TAVI ein Warnzeichen

10.06.2024 TAVI Nachrichten

Kommt es nach einem Transkatheter-Aortenklappen-Ersatz zu einem deutlichen Rückgang der Hämoglobinwerte, obwohl keine Blutung vorliegt, ist die Kliniksterblichkeit ähnlich hoch wie bei einem Rückgang mit Blutung. 

Hohe Morbidität und Mortalität bei rheumatischer Herzkrankheit

In Schwellen- und Entwicklungsländern ist die rheumatische Herzkrankheit nach wie vor ein Problem der öffentlichen Gesundheit. In einer weltweiten Bestandsaufnahme wurden aktuell die häufigsten Todesursachen der Patientinnen und Patienten zusammengetragen.

Erst wegen Herzinsuffizienz im Krankenhaus – und dann zur Dialyse

07.06.2024 Chronische Herzinsuffizienz Nachrichten

Bei älteren Menschen, die wegen Herzinsuffizienz stationär behandelt wurden, sollten Maßnahmen zum Erhalt der Nierenfunktion Priorität haben. Das machen die Komplikationsraten in einem US-amerikanischen Register deutlich. 

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.